Alder BioPharmaceuticals to Present New Phase 3 Migraine Prevention Data for Eptinezumab
BOTHELL, Wash., April 18, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will present new Phase 3 data for eptinezumab, Alder's lead investigational product candidate for migraine prevention, at the 70th Annual American Academy of Neurology Meeting (AAN) in Los Angeles being held April 21-27, 2018.
Eptinezumab will be the subject of eight scientific presentations. These will include new data from Alder’s PROMISE 1 Phase 3 clinical trial in episodic migraine patients following the third and fourth quarterly infusions (i.e., 12-month data) and improvement in patients’ quality of life measures following a single quarterly infusion. Data from the Company’s PROMISE 2 Phase 3 clinical trial in chronic migraine patients has also been selected for one of AAN’s two plenary presentation sessions on Emerging Science clinical trials.
Eptinezumab is an investigational monoclonal antibody targeting calcitonin gene-related peptide (CGRP) for migraine prevention. Eptinezumab’s mAb design, combined with delivery via quarterly infusion, allows for strong and immediate inhibition of CGRP biology. Eptinezumab has been studied in several global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention.
Migraine affects 36 million Americans and, worldwide, is considered the sixth-leading cause of days with disability and the third-leading cause of disability of people under the age of 50. The occurrence of migraine can be unpredictable with a profound impact on activities of daily living. This disease can last decades, often during what should be the most productive years of patients’ lives. Current preventive treatments for migraine fail to meet the needs of most patients and most patients discontinue use within 6 months to 1 year due to lack of efficacy and/or side effects. There is a significant need for new, effective, and well-tolerated treatment options.
About Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated as potentially the first-to-market migraine prevention infusion therapy. Eptinezumab is a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide (CGRP), which is believed to play a key role in mediating and initiating migraine.